Aug 21, 2019 3-5PM ET
Wednesday on The Robert Scott Bell Show:
Hour 1 – vScienceBites With Dr. Sherri Tenpenny!
“Small bites you can remember
– to bite them in the behind”
vScience Bites Radio
small bites you can remember
to bite them in the behind
Meningitis B and the Meningitis B Vaccines, Part 2
Date: August 21, 2019
Text MVI to 555888 to join our email list
Recap Part 1
1. The Illness
2. The incidence of infection – rare!
3. History of the vaccines – and current use
4. The Push for College Students
Part 2: Meningitis Serotype B
Today, we’re going to discuss the two newest meningitis vaccines specifically for serogroup B: Trumenba and Bexsero.
Recall that the meningitis vaccines generate antibodies against four of the most common Neisseria meningitis serotypes that have been found to cause meningitis: A/C/Y/WI-135. However, the most common serotype showed to cause the infection about 52% of the time in the US and about 90% of the time in Europe is serotype B.
Why was serotype B not included in the original vaccines? Because the surface antigens on the serotype B bacteria cross-react with brain tissue, increasing the risk of brain inflammation and brain autoimmunity.
REFERENCE: 1983 Lancet – full text
Finne J, et al. “Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.” Lancet. 1983 Aug 13;2(8346):355-7.https://www.ncbi.nlm.nih.gov/pubmed/6135869
Here’s an article from 2012, confirming the same findings from 1983:
“Development of conjugate vaccines against group B strains, however, has been hampered by cross-reactivity of the group B polysaccharide with host molecules and safety concerns about the potential to elicit [brain] auto-reactive antibodies.
REFERENCE: 2012 – PLOS – Full text
Beernink PT, et al. “The Effect of Human Factor H on Immunogenicity of Meningococcal Native Outer Membrane Vesicle Vaccines with Over-Expressed Factor H Binding Protein.” PLOS Pathogens 8(5): e1002688.https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002688#ppat.1002688-Finne1
Trumenba and Bexsero
In 2014, the first meningococcal serogroup B vaccine was released. Pfizer received FDA approval for TRUMENBA through an “accelerated” or fast track, approval process. It was only studied for 5 months and the trials included less than 4600 healthy individuals who were 11 to 18yrs – even though it was approved for use in individuals from 10 to 25 yrs. TRUMENBA can be administered as a two‐ or three‐dose schedule to adolescents and young adults, depending on “an individual’s risk of exposure and susceptibility to MenB.” It is not given routinely.
The following year, in 2015, GSK received approval for its serogroup B vaccine, BEXSERO. GSK got the benefit of an unapproved clinical train when several students at Princeton University contracted meningococcal serogroup B infection. Even though the vaccine application had been denied approval in Europe three times, the FDA allowed Princeton students to receive the vaccine – and when there were no reported side effects, this unofficial “trail” allowed the FDA to give the vaccine a fast-track pass for approval within 10 months.
In 2015, ACIP refused to approve the men B vaccines for routine use, stating that at best, it would only prevent approximately 9 cases and 1 death among college students.
In February of 2017, Sanofi Pasteur announced the discontinuation of the Menomune tetravalent meningococcal polysaccharide vaccine which is now replaced by Menactra and Menevo. Recall the Menomune was the first meningitis vaccine approved and has long contained 25mcg of Thimerosal per dose. If you review the VAERS database on meningitis vaccines, the vast number of reported adverse events that have been reported on the meningitis vaccines were reported about Menomune.
At around the same time, In response, the CDC announced that persons 56 years of age and older recommended to receive meningococcal vaccination be administered meningococcal conjugate vaccine. This recommendation was made despite acknowledging that neither available meningococcal conjugate vaccine is FDA approved for use in persons older than 55 years of age.
In 2018, Trumenba was approved for use in children ages 1 through 9 yrs.
Men B vaccine ingredients
• 0.519 mg Aluminum hydroxide = 500mcg
• 0.018 mg – Polysorbate
Meningitis Vaccine Side effects
The CDC reported that by February, 2008, 26 confirmed cases of GBS following Menactra had been reported to the Vaccine Adverse Event Reporting System (VAERS). Guillian-Barre is a type of paralysis with potentially long term complications.
Of course, TPTB pulled out all stops to maneuver the data – such as making very large numbers in the numerator – to disprove any connection between the vaccine and GBS.
Wouldn’t they be further off to just acknowledge that adverse reactions CAN AND DO occur?
Since the approval of the two meningitis B vaccines, there have been 7,205 adverse events reported from VAERS. Now, some of these reports show multiple vaccines were given at the same time, but some serious events were reported with the Men B vaccine was given alone. Perhaps the big dose of aluminum had something to do with it…
If you want to take a deeper dive into the specifics of this information, I wrote and posted an article called , “18 little known facts about College Meningitis Vaccines” that you can find by going to www.Vaxxter.com and putting “meningitis” in the search.
A Note about the New Vaxxter.com
We are working hard at Vaxxter.com to bring readers evidence-based, in-depth information and we have no intention of slowing down. I’ve attracted a stable of strong writers and we have some edgy topics lined up for the future.
While Vaxxter’s primary focus will always remain on vaccines, we plan to also delve into medical and humanitarian topics that expose problems in our healthcare system, our government, and our world.
If we don’t push the envelope to discuss difficult topics, nothing will ever change.
We know some of our readers are not going to be pleased with some of our upcoming information about vaccines and other topics, but that makes the information no less true. We don’t aim to be “politically correct” – we’re aiming at exposing the truth with facts and references you won’t hear about anywhere else.
We realize we can never please everyone, but we hope you’ll stay with us. Expand your thinking and stretch your views as we expose and explore the facts with you.
Links: AS OF NEXT WEEK – GO TO www.Courses4Mastery.com
Boot Camp Early notification – go to www.MasteringVaccineInfo.com
The New Vaxxter: – go to www.Vaxxter.com
Hour 2 – Outside The Box With Ty Bollinger!
It’s time to go Outside The Box again with Ty Bollinger! What will we be talking about today?
UK Anti-Vaccination Movement ‘Being Allowed To Thrive Online’ Unregulated online forums give anti-vaccination “quacks and cowboys” a free hand to peddle conspiracy theories and market dodgy “miracle cures”, a new study has found. Campaigning Labour MP Lucy Powell is calling on the government to act after she uncovered that so-called anti-vaxx groups on Facebook now have more than 800,000 members. Where information is public, her team found UK-based moderators peddling dangerous myths about “establishment cover-ups” and dodgy “scientific studies” claiming vaccinated children were more likely to suffer from hayfever, eczema, learning disabilities, ADHD, autism and chronic illness.
U.S. won’t give flu vaccines to migrants in border detention centers The U.S. government will not give flu vaccines to migrant families being held in detention centers near the U.S.-Mexico border. Customs and Border Protection (CBP) announced the decision Tuesday, weeks before the flu season begins. “In general, due to the short term nature of CBP holding, the time the vaccine takes to begin working, and the complexities of operating vaccination programs, neither CBP nor its medical contractors administer vaccinations to those in our custody,” a CBP spokesman said in a statement to CBS News. The spokesman did not respond to further questions about the policy. The U.S. will not provide vaccines for migrants — even after three migrant children have died in the past year .
We’re One Step Closer to a Blood Test that Predicts When a Person Will Die While death is inevitable, knowing when it will come isn’t necessarily, and scientists have been trying to develop a test that could reliably and easily predict how long a person will live — or, more technically, how healthy they are and therefore how vulnerable they might be to major mortality risk factors. Blood tests are the most likely avenue to such a test, since it’s easy to obtain blood samples and labs equipped to handle them are common. The latest effort is described in a new paper published in Nature Communications, by a team led by Joris Deelen, postdoctoral researcher at the Max Planck Institute for the Biology of Aging and P. Eline Slagboom, head of molecular epidemiology at Leiden University Medical Center. The researchers report that, in a group of more than 44,000 healthy patients, their blood test was around 80% accurate in predicting mortality risk within five to 10 years.
This 3-Day Event Will Change Your Life At The Truth About Cancer, when it comes to your health, we know that you want to be empowered and educated. In order to do that, you need access to trustworthy, life-saving data. The problem is that there is a lack of unbiased, credible information available, which makes you feel overwhelmed, confused, and afraid. We believe everyone deserves to know the TRUTH about cancer. We understand that at times it can be overwhelming. We’ve been there, which is why we began this mission over 20 years ago. We are excited to announce a “gathering” that will help remove the confusion and the fear and enlighten you with all the information you need to know in order to prevent and beat cancer.
Remember Friends, The Power to Heal is Yours!
More upcoming RSB events:
- Cancer Control Society 47th Annual Cancer Convention Aug. 31, Sept. 1 & 2, 2019 Glendale, CA
- The Truth About Cancer LIVE Oct 11-13 2019 Anaheim, CA
- Trinity Health Freedom Expo Oct 26-27 2019 Tinley Park, IL